Validation of DNA promoter hypermethylation biomarkers in breast cancer - A short report

Cellular Oncology

Volumn 37, Issue 4, 2014, Pages 297-303

  De Groot, Jolien S ^a   Pan, Xiaojuan ^a   Meeldijk, Jan ^a   Van Der Wall, Elsken ^a   Van Diest, Paul J ^a   Moelans, Cathy B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Biomarkers; Breast cancer; DNA promoter hypermethylation; Early detection; Validation

Indexed keywords

BIOLOGICAL MARKER; AKR1B1 PROTEIN, HUMAN; ALDEHYDE REDUCTASE; ALX1 PROTEIN, HUMAN; GHRELIN RECEPTOR; GPX7 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MEMBRANE PROTEIN; PEROXIDASE; SFRP2 PROTEIN, HUMAN; TM6SF1 PROTEIN, HUMAN; TMEFF2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER GENETICS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY;

ALDEHYDE REDUCTASE; BREAST NEOPLASMS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PEROXIDASES; PROMOTER REGIONS, GENETIC; RECEPTORS, GHRELIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84906935695     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-014-0189-1     Document Type: Article

References (32)

1. WHO, Breast cancer: prevention and control. http://www.who.int/cancer/ detection/breastcancer/en/. Accessed 30 June 2014
2. A. Algamas-Dimantov, E. Yehuda-Shnaidman, I. Peri, B. Schwartz, Epigenetic control of HNF-4alpha in colon carcinoma cells affects MUC4 expression and malignancy. Cell. Oncol. 36, 155-167 (2013)
3. Y. You, W. Yang, Z. Wang, H. Zhu, H. Li, C. Lin, Y. Ran, Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas. Cell. Oncol. 36, 323-331 (2013)
4. L.H. Jensen, A.A. Rasmussen, L. Byriel, H. Kuramochi, D.G. Cruger, J. Lindebjerg, P.V. Danenberg, A. Jakobsen, K. Danenberg, Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: A descriptive and prognostic cancer marker study. Cell. Oncol. 36, 411-419 (2013)
5. A. Geurts van Kessel, The cancer genome: From structure to function. Cell. Oncol. 37, 155-165 (2014)
6. K.P. Suijkerbuijk, M.J. Fackler, S. Sukumar, C.H. van Gils, T. van Laar, E. van der Wall, M. Vooijs, P.J. van Diest, Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann. Oncol. 19, 1870-1874 (2008)
7. J.G. Herman, J.R. Graff, S. Myohanen, B.D. Nelkin, S.B. Baylin, Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 93, 9821-9826 (1996)
8. D.S. Shames, J.D. Minna, A.F. Gazdar, Methods for detecting DNA methylation in tumors: From bench to bedside. Cancer Lett. 251, 187-198 (2007)
9. P.J. van Diest, No consent should be needed for using leftover body material for scientific purposes. BMJ 325, 648-651 (2002)
10. T. Swift-Scanlan, R. Vang, A. Blackford, M.J. Fackler, S. Sukumar, Methylated genes in breast cancer: Associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol. Ther. 11, 853-865 (2011)
11. M.J. Fackler, C.B. Umbricht, D.Williams, P. Argani, L.A. Cruz, V.F. Merino, W.W. Teo, Z. Zhang, P. Huang, K. Visvananthan, J. Marks, S. Ethier, J.W. Gray, A.C. Wolff, L.M. Cope, S. Sukumar, Genome- wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res. 71, 6195-6207 (2011)
12. M.J. Fackler, Z.L. Bujanda, C. Umbricht, W.W. Teo, S. Cho, Z. Zhang, K. Visvanathan, S. Jeter, P. Argani, C. Wang, J.P. Lyman, M. de Brot, J.N. Ingle, J. Boughey, K. McGuire, T.A. King, L.A. Carey, L. Cope, A.C. Wolff, S. Sukumar, Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res. 74, 2160-2170 (2014)
13. NCBI Gene, AKR1B1 aldo-keto reductase family 1, member B1 (aldose reductase) [Homo sapiens (human)]. http://www.ncbi.nlm.nih.gov/gene/231. Accessed 30 June 2014
14. R. Tammali, S.K. Srivastava, K.V. Ramana, Targeting aldose reductase for the treatment of cancer. Curr. Cancer Drug Targets 11, 560-571 (2011)
15. N. Hevir, J. Sinkovec, T. Lanisnik Rizner, Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue. Chem. Biol. Interact. 202, 226-233 (2013)
16. B. Laffin, J.M. Petrash, Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers. Front. Pharmacol. 3, 104 (2012)
17. R. Tao, J. Li, J. Xin, J. Wu, J. Guo, L. Zhang, L. Jiang, W. Zhang, Z. Yang, L. Li, Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma. PLoS One 6, e19862 (2011)
18. F. Fang, S. Turcan, A. Rimner, A. Kaufman, D. Giri, L.G.Morris, R. Shen, V. Seshan, Q. Mo, A. Heguy, S.B. Baylin, N. Ahuja, A. Viale, J. Massaque, L. Norton, L.T. Vahdat, M.E. Moynahan, T.A. Chan, Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci. Transl. Med. 3, 75ra25 (2011)
19. R.T. Chatterton, M. Sahadevan, O. Lee, H. Hong, W. Jun, I. Helenowski, S. Sukumar, V. Stearns, M.J. Fackler, S.A. Khan, Single-strand breaks in normal breast DNA are associated with measures of breast cancer risk, deficiencies in repair mechanisms, and diminished protection against oxidative processes. Cancer Prev. Res. 5, A15 (2012)
20. S.K. Botla, A.M. Gholami, M. Malekpour, E.A. Moskalev, M. Fallah, P. Jandaghi, A. Aghajani, I.S. Bondar, R. Omranipour, F. Malekpour, A. Mohajeri, A.J. Bababi, O. Sahin, V.V. Bubnov, H. Najmabadi, J.D. Hoheisel, Y. Riazalhosseini, Diagnostic values of GHSR DNAmethylation pattern in breast cancer. Breast Cancer Res. Treat. 135, 705-713 (2012)
21. J. Jeschke, L. van Neste, S.C. Glockner, M. Dhir, M.F. Calmon, V. Deregowski, W. van Criekinge, I. Vlassenbroeck, A. Koch, T.A. Chan, L. Cope, C.M. Hooker, K.E. Schuebel, E. Gabrielson, A. Winterpacht, S.B. Baylin, J.G. Herman, N. Ahuja, Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 7, 701-709 (2012)
22. S.Y. Park, H.J. Kwon, H.E. Lee, H.S. Ryu, S.W. Kim, J.H. Kim, I.A. Kim, N. Jung, N.Y. Cho, G.H. Kang, Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch. 458, 73-84 (2011)
23. R. Krassenstein, E. Sauter, E. Dulaimi, C. Battagli, H. Ehya, A. Klein-Szanto, P. Cairns, Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin. Cancer Res. 10, 28-32 (2004)
24. M. Faryna, C. Konermann, S. Aulmann, J.L. Bermejo, M. Brugger, S. Diederichs, J. Rom, D. Weichenhan, R. Claus, M. Rehli, P. Schirmacher, H.P. Sinn, C. Plass, C. Gerhauser, Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J. 26, 4937-4950 (2012)
25. M.S. Kim, J. Lee, T. Oh, Y. Moon, E. Chang, K.S. Seo, B.D. Hoehn, S. An, J.H. Lee, Genome-wide identification of OTP gene as a novel methylation marker of breast cancer. Oncol. Rep. 27, 1681-1688 (2012)
26. H.N. Horne, P.S. Lee, S.K. Murphy, M.A. Alonso, J.A. Olson, J.R. Marks, Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.Mol. Cancer Res. 7, 199-209 (2009)
27. C. Fumagalli, G. Pruneri, P. Possanzini, M. Manzotti, M. Barile, I. Feroce, M. Colleoni, B. Bonnani, P. Maisonneuve, P. Radice, G. Viale, M. Barberis, Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res. Treat. 134, 131-137 (2012)
28. J. Klajic, T. Fleischer, E. Dejeux, H. Edvardsen, F. Warnberg, I. Bukholm, P.E. Lonning, H. Solvang, A.L. Borresen-Dale, J. Tost, V.N. Kristensen, Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer 13, 1-12 (2013)
29. Y. Alkam, H. Mitomi, K. Nakai, T. Himuro, T. Saito, M. Takahashi, A. Arakawa, T. Yao, M. Saito, Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer. Histopathology 63, 713-725 (2013)
30. A. Tserga, N.V. Michalopoulos, G. Levidou, P. Korkolopoulou, G. Zografos, E. Patsouris, A.A. Saetta, Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncol. Rep. 27, 1630-1638 (2012)
31. G. Sharma, S. Mirza, R. Parshad, A. Srivastava, S.D. Gupta, P. Pandya, R. Ralhan, Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci. 87, 83-91 (2010)
32. A.A. Muggerud, J.A. Ronneberg, F.Warnberg, J. Botling, F. Busato, J. Jovanovic, H. Solvang, I. Bukholm, A.L. Borresen-Dale, V.N. Kristensen, T. Sorlie, J. Tost, Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res. 12, R3 (2010)